Llwytho...
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
Trastuzumab is the standard treatment in Canada for patients with breast cancer positive for her2 (human epidermal growth factor receptor 2), dramatically improving outcomes in that patient group. However, its current intravenous (IV) administration is associated with long infusion times that place...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Curr Oncol |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Multimed Inc.
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6380645/ https://ncbi.nlm.nih.gov/pubmed/30853812 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4220 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|